Soleus Capital Management’s Legend Biotech LEGN Stock Holding History

Soleus Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.8M	Buy	+1,205,000	New	+$32.5M	1.2%	25

Other funds holding LEGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

IAMH

IvyRock Asset Management (HK) Sheung Wan, Hong Kong $177M AUM 10.49% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

Soleus Capital Management's LEGN Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 1,205,000 shares worth $34.8M. The stake represents 1.2% of the portfolio and ranks #25 among its holdings.

93 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Soleus Capital Management held 1,205,000 shares of Legend Biotech worth $34.8M as of Q2 2026.
Legend Biotech was a new Soleus Capital Management position in Q2 2026.
Legend Biotech made up 1.2% of Soleus Capital Management's portfolio in Q2 2026, its #25 holding.
93 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.